We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
+34.19%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$180B
AUM Growth
+$34.5B
Cap. Flow
+$124M
Cap. Flow %
0.07%
Top 10 Hldgs %
43.41%
Holding
443
New
192
Increased
135
Reduced
77
Closed
14

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.73B
2
ONC
BeOne Medicines Ltd
ONC
+$774M
3
ILMN icon
Illumina
ILMN
+$691M
4
DXCM icon
DexCom
DXCM
+$438M
5
NFLX icon
Netflix
NFLX
+$360M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 37.71%
2 Technology 16.18%
3 Healthcare 15.43%
4 Communication Services 14.41%
5 Financials 5.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MCD icon
176
McDonald's
MCD
$195B
$38M 0.02%
177,176
-5
-0% -$1.09K
STRO icon
177
Sutro Biopharma
STRO
$421M
$36.8M 0.02%
169,565
BNR
178
Burning Rock Biotech
BNR
$92.9M
$36.4M 0.02%
157,756
+56,529
+56% +$15.2M
DMRC icon
179
Digimarc Corp
DMRC
$178M
$35.9M 0.02%
760,625
-773
-0.1% -$30.2K
RUBY
180
DELISTED
Rubius Therapeutics, Inc
RUBY
$35.7M 0.02%
4,710,061
+436,200
+10% +$2.59M
ARCC icon
181
Ares Capital
ARCC
$14.4B
$31.8M 0.02%
1,880,870
TRHC
182
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$31.6M 0.02%
738,793
+73,642
+11% +$2.8M
IQ icon
183
iQIYI
IQ
$1.28B
$31.6M 0.02%
1,809,256
+667,046
+58% +$15M
FARO
184
DELISTED
Faro Technologies
FARO
$31.5M 0.02%
446,108
+2,553
+0.6% +$169K
DLB icon
185
Dolby
DLB
$5.79B
$28.5M 0.02%
293,157
+3,317
+1% +$274K
TNDM icon
186
Tandem Diabetes Care
TNDM
$1.56B
$28.3M 0.02%
295,445
+176
+0.1% +$18.1K
SIMO icon
187
Silicon Motion
SIMO
$8.68B
$28M 0.02%
+581,441
New +$23.8M
CSCO icon
188
Cisco
CSCO
$479B
$27.3M 0.02%
610,056
-1,613
-0.3% -$66.3K
TROW icon
189
T. Rowe Price
TROW
$24.3B
$26.9M 0.02%
177,441
-178
-0.1% -$25.5K
EW icon
190
Edwards Lifesciences
EW
$51.7B
$25.6M 0.01%
280,311
+26,830
+11% +$2.23M
MDT icon
191
Medtronic
MDT
$112B
$24.5M 0.01%
208,747
-140
-0.1% -$15.4K
BILI icon
192
Bilibili
BILI
$7.84B
$24.2M 0.01%
282,426
+141,515
+100% +$8.29M
VECO icon
193
Veeco
VECO
$3.23B
$23.2M 0.01%
1,333,700
+14,041
+1% +$215K
NBTX
194
Nanobiotix
NBTX
$1.94B
$23.1M 0.01%
+1,400,000
New +$24.1M
WAT icon
195
Waters Corp
WAT
$39.9B
$23M 0.01%
93,091
-9,374
-9% -$2.12M
CEVA icon
196
CEVA Inc
CEVA
$1.08B
$22.1M 0.01%
486,512
+1,057
+0.2% +$43.4K
SIX
197
DELISTED
Six Flags Entertainment Corp.
SIX
$21.6M 0.01%
+634,800
New +$17.4M
CFR icon
198
Cullen/Frost Bankers
CFR
$10.2B
$20.9M 0.01%
239,337
+9,253
+4% +$727K
AXGN icon
199
Axogen
AXGN
$2.5B
$20.8M 0.01%
1,161,752
+81,068
+8% +$1.19M
HEI icon
200
HEICO Corp
HEI
$51.4B
$20.8M 0.01%
157,048
-5,800
-4% -$708K

Similar funds

Baillie Gifford & Co's Q4 2020 Portfolio in Review

As of Q4 2020, Baillie Gifford & Co held 443 positions worth $180B, up 24% from $145B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Baillie Gifford & Co's Q4 2020 filing shows 192 new, 135 increased, 77 reduced and 14 closed positions. Its largest new stake was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M. The largest sale was Tesla, an estimated $3.79B.

By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, up from 37% a quarter earlier, followed by Technology and Healthcare.

  • Baillie Gifford & Co's largest Q4 2020 buy was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M.
  • Baillie Gifford & Co added most to Moderna in Q4 2020, an estimated $1.73B increase.
  • Baillie Gifford & Co's biggest Q4 2020 reduction was Tesla, cutting an estimated $3.79B.
  • Baillie Gifford & Co fully exited TD Ameritrade Holding Corp in Q4 2020, selling an estimated $264M.
  • Baillie Gifford & Co's ten largest holdings make up 43% of its $180B portfolio in Q4 2020.
  • Baillie Gifford & Co opened 192 new positions and closed 14 in Q4 2020.
  • Baillie Gifford & Co's portfolio value rose 24% quarter-over-quarter to $180B.

Based on Baillie Gifford & Co's 13F filing for Q4 2020, filed 10 Feb 2021.